-
Exagamglogene autotemcel, sold
under the
brand name Casgevy, is a gene
therapy used for the
treatment of
sickle cell
disease and transfusion-dependent...
- of the Year
Award (FOYA)
award in 2022. The company’s lead program,
exagamglogene autotemcel, or exa-cel (formerly CTX001), was
granted regulatory approval...
-
blood cells.
Healthy hemoglobin A is
generated resolving the anemia.
Exagamglogene autotemcel, sold
under the
brand name Casgevy, is a gene
therapy for...
-
blood cells.
Healthy hemoglobin A is
generated resolving the anemia.
Exagamglogene autotemcel, sold
under the
brand name Casgevy, is a gene
therapy for...
-
which a
number of
patients were
successfully treated. In 2023, both
exagamglogene autotemcel (Casgevy) and
lovotibeglogene autotemcel (Lyfgenia) were...
-
first injection of the CRISPR-Cas
System was
confirmed in
March 2020.
Exagamglogene autotemcel, a CRISPR-based
human gene
editing therapy, was used for...
-
Betibeglogene autotemcel B06AX03
Voxelotor B06AX04
Mitapivat B06AX05
Exagamglogene autotemcel "ATC (Anatomical
Therapeutic Chemical classification System)...
-
Evenity everolimus (USAN) Evex
Evista Evolo****ab (INN)
Evoxac Evrysdi exagamglogene autotemcel (USAN, INN)
exalamide (INN)
exametazime (INN) examorelin...
-
Etranacogene dezaparvovec (Hemgenix): AAV-based
treatment for
hemophilia B
Exagamglogene autotemcel (Casgevy):
treatment for
sickle cell disease. Gendicine:...
- Casgevy, to
treat sickle-cell
anemia and beta thal****emia. Casgevy, or
exagamglogene autotemcel,
directly acts on the
genes of the stem
cells inside the...
